Royce & Associates LP Grows Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Royce & Associates LP lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 13.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,119,385 shares of the medical instruments supplier’s stock after buying an additional 133,312 shares during the quarter. Royce & Associates LP’s holdings in AngioDynamics were worth $10,254,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in ANGO. SBI Securities Co. Ltd. bought a new position in AngioDynamics during the 4th quarter valued at $28,000. R Squared Ltd bought a new stake in shares of AngioDynamics in the 4th quarter worth about $49,000. US Bancorp DE raised its stake in shares of AngioDynamics by 1,938.0% in the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier’s stock valued at $61,000 after purchasing an additional 6,376 shares in the last quarter. Quarry LP lifted its position in shares of AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 2,471 shares during the last quarter. Finally, SG Americas Securities LLC grew its stake in AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after purchasing an additional 2,832 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

Insider Transactions at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total transaction of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright upped their price objective on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Price Performance

ANGO stock opened at $9.59 on Tuesday. The firm has a market cap of $388.07 million, a price-to-earnings ratio of -1.70 and a beta of 0.56. AngioDynamics, Inc. has a 1-year low of $5.26 and a 1-year high of $13.50. The firm has a fifty day moving average price of $10.83 and a two-hundred day moving average price of $8.65.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. During the same quarter in the prior year, the firm earned ($0.05) EPS. The company’s revenue for the quarter was down .1% compared to the same quarter last year. As a group, analysts expect that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.